—

declare the application admissible and well-founded;

—

annul the Commission’s Implementing Regulation (EU) 2020/2087 concerning the non-renewal of the approval of the active substance mancozeb, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011 (1) (‘the Contested Act’); and,

—

order the defendant to pay the costs of these proceedings.

1.

First plea in law, alleging that an essential procedural requirement has been infringed by a failure to comply with the procedure in Articles 11 to 14 of Regulation 844/2012. (2)

2.

Second plea in law, alleging that the assessment procedure has been further vitiated by an infringement of the applicants’ rights of defence.

3.

Third plea in law, alleging that the assessment procedure was vitiated by an infringement of the principle of sound and good administration, and the defendant’s failure to act with impartiality in the course of the procedure.

4.

Fourth plea in law, alleging that the assessment procedure has been vitiated by a manifest error of assessment in that the defendant took the irrelevant facts of the proposed Reprotoxic 1B classification and the intrinsic properties of the substance’s metabolite ETU into account.

5.

Fifth plea in law, alleging that the assessment procedure has been vitiated by an infringement of the principle of legitimate expectation.